Preliminary Scientific Program

PRELIMINARY PROGRAM SUBJECT TO CHANGE

RISK FACTORS FOR ATRIAL FIBRILLATION - Pathophysiology, Clinical Impact and Therapeutic Strategies

AF Under Age 40 - Genetic Testing Before Ablation?

Sleep Apnea and AF: Where Do We Stand? - Practical Advice for Clinicians

Aggressive Weight Loss as Adjunctive Therapy for AF - Rationale, Clinical Data and Future Clinical Trials

Inflammation and AF: Overview and Potential Novel Therapeutic Target 2-HOBA

SPOTLIGHT SESSION: Early Stage and Emerging Technologies in Cardiac Electrophysiology

Preliminary Presenters:
Ablacon
Acesion Pharma
BioSig Technologies
CardioNXT
Cardiva Medical
CathRx
Circle Cardiovascular Imaging
HUYA Bioscience
InCarda Therapeutics
Janssen Scientific
Javelin Medical
Kardium
LuxMed Systems
Manual Surgical Sciences
ReCor Medical
Sig.Num
Volta Medical
USFDA Regulatory Approaches to Facilitate Early Stage Device Innovation

10-10:30 AM: Break and Exhibits

NOVEL TECHNIQUES AND TECHNOLOGIES FOR CATHETER ABLATION OF AF
(Non-CME Session)

High Density Grid and Overcoming Bipolar Blindness to Map AF and Atrial Flutter

Elimination of All PVI Gaps: One Year Outcomes Using HD Mapping to Keep Redo Rates Below 10%

Using HD Grid to Map Voltage and Drivers in Atrial Fibrillation

The Hospital Economics of AF Ablation

Case Presentations

Panel and Audience Discussion and Q&A

Noon-1:15 PM: Lunch, Exhibits and Product Theaters

STROKE PREVENTION IN AF: SESSION I - SCREENING AND ANTICOAGULATION

Consumer Devices for AF Detection and Continuous Monitoring: Current Status and Future Promise

Update on Device-Detected AF and Stroke Risk as a Function of AF Burden - Clinical Implications

Artificial Intelligence-Enabled ECG Algorithm for Identification During Sinus Rhythm of Patients with AF - Implications for AF Screening and Management of Cryptogenic Stroke

Rationale and Feasibility of “As Needed" NOACs for Infrequent AF Episodes Following AF Ablation Guided by Diligent Pulse Monitoring

Oral Factor XIa Inhibitors: Current & Future Clinical Trials & Potential Advantages over NOACs

STROKE PREVENTION IN AF: SESSION II - LEFT ATRIAL APPENDAGE CLOSURE AND CAROTID PROTECTION

Update on Clinical Trials with LAA Closure Devices

Head to Head Study of LAA Closure vs NOAC in High-Risk Patients with AF: PRAGUE 17 Trial

Anticoagulation and Antiplatelet Therapy After LAA Closure: What, When & How Long?

FDA Perspective on Left Atrial Appendage Closure Devices for Stroke Prevention

3:15-3:45 PM: Break and Exhibits

SESSION II - LEFT ATRIAL APPENDAGE CLOSURE (Continued)

Complications of LAA Closure Devices and Procedures - Prevention and Management

Future Technologies in Left Atrial Appendage Closure

Percutaneous Permanent Carotid Filter for Stroke Prevention in AF: CAPTURE and the Ongoing CAPTURE2 Trials

Case Transmission: Concomitant AF Ablation and LAA Closure

Panel and Audience Discussion and Q&A

7 - 10 PM
AF SYMPOSIUM 25th ANNIVERSARY DINNER CELEBRATION

All Attendees, Faculty and Industry

REAL-TIME CASE TRANSMISSIONS: New Directions in Imaging, Mapping and Ablation Panel and Audience Discussions

Ultra-Low Temperature Cryoablation for Atrial Fibrillation

Dipole Density Mapping of Atrial Fibrillation

Panel & Audience Q&A and Discussion

8:45-8:55 AM: Break

REAL-TIME CASE TRANSMISSIONS: New Directions in Imaging, Mapping and Ablation Panel and Audience Discussions

High-Power Temperature Controlled RF Ablation for Non-PV Triggers

Pulsed Field Ablation for Atrial Fibrillation (Pre-recorded Case)

Panel & Audience Discussion and Q&A

10-10:30 am: Break and Exhibits

STATE OF THE ART IN ADVANCED MAPPING AND CATHETER ABLATION FOR AF: Improving Efficacy and Efficiency
(Non-CME Session)

Maximizing the Value of 3-D Mapping and Ultrasound to Reduce Radiation Exposure

Advanced Techniques for Mapping Complex Atrial Arrhythmias

Maximizing Lesion Efficacy and Reducing Gaps in AF Ablation

ATTEST Trial - Impact of Catheter Ablation on Progression from Paroxysmal to Persistent AF

Panel and Audience Discussion and Q&A

Noon-1:15 PM: Lunch, Exhibits and Product Theaters

ADVANCES IN PULMONARY VEIN ISOLATION - A NEW ERA

(Session I) Energy Sources, Delivery Strategies and New Technologies for AF Ablation

Rate of PV Reconnection: Magnitude of the Problem in 2020

High-Power Short Duration Ablation Using Currently Available RF Catheters

Ultra-High-Power, Short Duration Temperature Controlled Ablation with Novel RF Technology

Radiofrequency Balloons for Pulmonary Vein Isolation

Ultra-Low Temperature Linear Cryoablation for AF: Clinical Results

Novel Cryoballoon Technologies for AF Ablation - Clinical Outcomes

Particle Therapy Ablation - Outcome of Phase I Studies

3:15-3:45 PM: Break

ADVANCES IN PULMONARY VEIN ISOLATION

(Session II) Cardiac Pulsed Field Ablation/Irreversible Electroporation

Introduction to the Science of Pulsed Field Ablation/Electroporation

Current Status of Pulsed Field Ablation/Cardiac Electroporation for Pulmonary Vein Isolation: Safety and Efficacy

Future Directions in Pulsed Field Ablation/Cardiac Electroporation: Linear Lesions and Persistent AF

Panel and Audience Discussion and Q&A

LATE-BREAKING CLINICAL TRIALS AND FIRST REPORT CLINICAL INVESTIGATIONS

BEST ABSTRACT AWARD

BEYOND PVI - ANATOMICAL VS ELECTROPHYSIOLOGICAL TARGETS FOR AF ABLATION

Repetitiveness of Spatiotemporal Patterns of AF As Determinant of AF Stability

Using Instantaneous Amplitude and Frequency Modulation to Detect the Footprint of Stable Driver Regions as Targets for Ablation of Persistent AF

Comparison of High Resolution Experimental Optical Mapping and Catheter Mapping of AF

De-Channeling Scar During Redo AF and Flutter Ablations: New Substrate-Based Approach

How to Modify the Atrial Substrate in Patients with Longstanding Persistent AF

Computationally Guided Personalized Targeted Ablation for Persistent AF

9:30-10:30 AM: Continental Breakfast and Exhibits

BEYOND PVI- ANATOMICAL VS ELECTROPHYSIOLOGICAL TARGETS FOR AF ABLATION (Continued)

Comparison of Anatomical vs. Electrophysiological Procedure for Persistent AF - A Multicenter Study

Left Atrial Appendage Isolation - Impact on Long-Term Arrhythmia Recurrence and Systemic Thromboembolism

Recent Trials in Persistent AF: Toward a Uniform Strategy or Individualized Approaches?

Panel and Audience Discussion and Q&A

IMPROVING THE SAFETY, EFFECTIVENESS AND EFFICIENCY OF AF ABLATION

New Data Regarding Esophageal Injury with High-Power-Short-Duration Ablation

How to Improve the Safety, Efficiency and Cost of AF Ablation Procedures

12:30 PM: Working Lunch Buffet in Meeting Hall

OUTCOMES TRIALS IN AF ABLATION RESULTS, IMPLICATIONS FOR CLINICAL PRACTICE AND FUTURE STUDIES

New Output from the CABANA Trial: The Effect of NSR Regardless of Treatment Strategy

Outcomes and Clinical Implications of AF Ablation Trials in Patients with Heart Failure

Recurrence of AF 10 years After Index PVI and Proven PV Isolation: Is This A New Disease?

New Approaches to Measuring Outcomes of AF Ablation - Is a 30-Second Recurrence a Meaningful Endpoint?

What CABANA Has Taught Us: A Regulatory Perspective

Panel and Audience Discussion and Q&A

CHALLENGING CASES IN AF MANAGEMENT: Anticoagulation, Antiarrhythmic Drugs and Catheter Ablation for AF
Panel and Audience Discussion and Q&A

Adjourn

REGISTRATION & BADGE PICK-UP

Wednesday, January 22
Noon - 6:30 PM

Thursday, January 23 and Friday, January 24
6:30 AM - Close

EXPO HALL OPENS

Thursday, January 23
9 AM – 4:30 PM